James Sax1, Michael Karpa1, Ian Reddie2. 1. The Townsville Hospital, Douglas, Queensland, Australia; and. 2. Townsville Eye Care, Mundingburra, Queensland, Australia.
Abstract
PURPOSE: To draw attention to a novel treatment agent for vision loss associated with peripheral exudative hemorrhagic chorioretinopathy. METHODS: The case of an 83-year-old man suffering with loss of left visual acuity vision in the context of vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy is described. RESULTS: Resolution of vitreous hemorrhage and subretinal hemorrhage was demonstrated after treatment with aflibercept. CONCLUSION: Peripheral exudative hemorrhagic chorioretinopathy is discussed in terms of its presentation, pathophysiology, and existing treatment methodologies.
PURPOSE: To draw attention to a novel treatment agent for vision loss associated with peripheral exudative hemorrhagic chorioretinopathy. METHODS: The case of an 83-year-old man suffering with loss of left visual acuity vision in the context of vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy is described. RESULTS: Resolution of vitreous hemorrhage and subretinal hemorrhage was demonstrated after treatment with aflibercept. CONCLUSION: Peripheral exudative hemorrhagic chorioretinopathy is discussed in terms of its presentation, pathophysiology, and existing treatment methodologies.